Shamilene Sivagnanam
Overview
Explore the profile of Shamilene Sivagnanam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berens E, Khou S, Huang E, Hoffman A, Johnson B, Kirchberger N, et al.
bioRxiv
. 2025 Feb;
PMID: 39896558
Statement Of Significance: Neoplastic breast epithelial cells express surface receptors canonically attributed to leukocytes and are associated with therapy resistance and aggressive tumor behavior.
2.
Ehlers F, Blise K, Betts C, Sivagnanam S, Kooreman L, Hwang E, et al.
Breast Cancer Res
. 2025 Jan;
27(1):14.
PMID: 39856748
Tumor-infiltrating lymphocytes are considered clinically beneficial in breast cancer, but the significance of natural killer (NK) cells is less well characterized. As increasing evidence has demonstrated that the spatial organization...
3.
Mi H, Sivagnanam S, Betts C, Liudahl S, Jaffee E, Coussens L, et al.
Cancer Res
. 2024 Nov;
84(21):3701.
PMID: 39492679
No abstract available.
4.
Mi H, Sivagnanam S, Ho W, Zhang S, Bergman D, Deshpande A, et al.
Brief Bioinform
. 2024 Aug;
25(5).
PMID: 39179248
Advancements in imaging technologies have revolutionized our ability to deeply profile pathological tissue architectures, generating large volumes of imaging data with unparalleled spatial resolution. This type of data collection, namely,...
5.
Blise K, Sivagnanam S, Betts C, Betre K, Kirchberger N, Tate B, et al.
Cancer Immunol Res
. 2024 Feb;
12(5):544-558.
PMID: 38381401
Tumor molecular data sets are becoming increasingly complex, making it nearly impossible for humans alone to effectively analyze them. Here, we demonstrate the power of using machine learning (ML) to...
6.
Blise K, Sivagnanam S, Betts C, Betre K, Kirchberger N, Tate B, et al.
bioRxiv
. 2023 Nov;
PMID: 37961410
Tumor molecular datasets are becoming increasingly complex, making it nearly impossible for humans alone to effectively analyze them. Here, we demonstrate the power of using machine learning to analyze a...
7.
Brockman A, Khurana R, Bartkowiak T, Thomas P, Sivagnanam S, Betts C, et al.
Cytometry B Clin Cytom
. 2023 Feb;
104(5):344-355.
PMID: 36748312
Cyclic immunohistochemistry (cycIHC) uses sequential rounds of colorimetric immunostaining and imaging for quantitative mapping of location and number of cells of interest. Additionally, cycIHC benefits from the speed and simplicity...
8.
Sinha M, Betts C, Zhang L, Griffith M, Solman I, Chen B, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36593070
Background: In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy. This led to a phase 1b clinical trial to determine...
9.
Mi H, Sivagnanam S, Betts C, Liudahl S, Jaffee E, Coussens L, et al.
Cancer Res
. 2022 Sep;
82(23):4359-4372.
PMID: 36112643
Significance: Quantitative image analysis of PDAC specimens reveals intertumoral and intratumoral heterogeneity of immune populations and identifies spatial immune architectures that are significantly associated with disease prognosis.
10.
Sundaram S, Kim E, Jones G, Sivagnanam S, Tripathi M, Miremadi A, et al.
Front Immunol
. 2022 Jun;
13:874255.
PMID: 35663986
Esophageal adenocarcinoma (EAC) develops from a chronic inflammatory environment across four stages: intestinal metaplasia, known as Barrett's esophagus, low- and high-grade dysplasia, and adenocarcinoma. Although the genomic characteristics of this...